Evidence map›Paper›PMID 40284493›Full record

ReviewPharmaceutics2025

Applications and Efficacy of Iron Oxide Nanoparticles in the Treatment of Brain Tumors.

London Varalli, Reed Berlet, E C Abenojar, John McDaid, David A Gascoigne, Julian Bailes, Daniil P Aksenov

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

London VaralliDepartment of Radiology, Endeavor Health, Evanston, IL 60201, USA.
Reed BerletSchool of Medicine and Science, Rosalind Franklin University, North Chicago, IL 60064, USA.
E C AbenojarDepartment of Chemistry, Northwestern University, Evanston, IL 60208, USA.ORCID 0000-0002-2733-4006
John McDaidDepartment of Neurosurgery, Endeavor Health, Evanston, IL 60201, USA.
David A GascoigneDepartment of Radiology, Endeavor Health, Evanston, IL 60201, USA.
Julian BailesDepartment of Neurosurgery, Endeavor Health, Evanston, IL 60201, USA.
Daniil P AksenovDepartment of Radiology, Endeavor Health, Evanston, IL 60201, USA.ORCID 0000-0003-4599-0290

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancers of the central nervous system are particularly difficult to treat due to a variety of factors. Surgical approaches are impeded by the skull-an issue which is compounded by the severity of possible harm that can result from damage to the parenchymal tissue. As a result, chemotherapeutic agents have been the standard of care for brain tumors. While some drugs can be effective on a case-by-case basis, there remains a critical need to improve the efficacy of chemotherapeutic agents for neurological cancers. Recently, advances in iron oxide nanoparticle research have highlighted how their unique properties could be leveraged to address the shortcomings of conventional therapeutics. Iron oxide nanoparticles combine the advantages of good biocompatibility, magnetic susceptibility, and functionalization via a range of coating techniques. Thus, iron oxide nanoparticles could be used in both the imaging of brain cancers with magnetic resonance imaging, as well as acting as trafficking vehicles across the blood-brain barrier for targeted drug delivery. Moreover, their ability to support minimally invasive therapies such as magnetic hyperthermia makes them particularly appealing for neuro-oncological applications, where precision and safety are paramount. In this review, we will outline the application of iron oxide nanoparticles in various clinical settings including imaging and drug delivery paradigms. Importantly, this review presents a novel approach of combining surface engineering and internal magnetic targeting for deep-seated brain tumors, proposing the surgical implantation of internal magnets as a next-generation strategy to overcome the limitations of external magnetic fields.

Indexed as

drug deliveryiron oxide nanoparticlesneurological cancer

Identifiers

PMID40284493
PMCPMC12030199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.